ProKidney Corp’s recent filing unveils that its Add’l Rep. Persons-see Ex.99-1 Control Empresarial de Capital acquired Company’s shares for reported $0.28 million on Apr 22 ’25. In the deal valued at $0.71 per share,387,393 shares were bought. As a result of this transaction, Control Empresarial de Capital now holds 73,842,723 shares worth roughly $73.1 million.
Then, Control Empresarial de Capital bought 25,000 shares, generating $18,690 in total proceeds. Upon buying the shares at $0.75, the Add’l Rep. Persons-see Ex.99-1 now owns 73,455,330 shares.
Before that, Control Empresarial de Capital bought 100,000 shares. ProKidney Corp shares valued at $74,820 were divested by the Add’l Rep. Persons-see Ex.99-1 at a price of $0.75 per share. As a result of the transaction, Control Empresarial de Capital now holds 73,430,330 shares, worth roughly $72.7 million.
JP Morgan initiated its ProKidney Corp [PROK] rating to a Neutral in a research note published recently. A number of analysts have revised their coverage, including Guggenheim’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. BofA Securities revised its rating on January 02, 2024. It rated PROK as “a Neutral” which previously was an “a Buy”.
Price Performance Review of PROK
On Monday, ProKidney Corp [NASDAQ:PROK] saw its stock jump 17.65% to $0.99. Over the last five days, the stock has gained 0.64%. ProKidney Corp shares have fallen nearly -41.64% since the year began. Nevertheless, the stocks have fallen -67.01% over the past one year. While a 52-week high of $3.05 was reached on 01/06/25, a 52-week low of $0.46 was recorded on 04/09/25.
Levels Of Support And Resistance For PROK Stock
The 24-hour chart illustrates a support level at 0.8787, which if violated will result in even more drops to 0.7710. On the upside, there is a resistance level at 1.0520. A further resistance level may holdings at 1.1176.
The most recent change occurred on July 25, 2023 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $16 price target.
